 Kadmon Holdings Inc. said Friday that Rezurock, its treatment of chronic graft-versus-host disease cGVHD in adjusts and pediatric patients older than 12 was approved by the Food and Drug Administration. The biopharmaceutical companys stock, which has been halted for news until 2:45 p.m. 